NASDAQ : AMGN

Amgen Inc.

$376.04 USD

$4.54 (1.22%)

Volume
2.49M
Average Volume
2.72M
Market Capitalization
$202.95B
P/E Ratio
25.97
Dividend Yield
2.61%
Price Target
$360.00
Year High
$391.29
Year Low
$269.77
Day High
—
Day Low
—
Payout Ratio
$0.67
Current Ratio
$1.26
Company Overview

NASDAQ

Robert A. Bradway

Drug Manufacturers - General

Healthcare

AMGN

31500

US

USD

https://www.amgen.com

805 447 1000

031162100

0000318154

Liquidity Metrics

6.24

1.26

1.01

0.48

0.67

Sales & Valuation

$36.74B

5.45

22.10

23.61

15.92

Profitability

$14.23

$7.71B

20.95%

24.40%

89.41%

8.43%

P/E Metrics

25.97

0.84

0.84

Analyst Price Target & Rating

$360.00

$427.00

$185.00

Neutral

3/5

38 Analysts

4.46%

Financial Health Scores

1.98

8/9

$6.52B

$92.5B

$83.31B

$11.79B

Key Metrics (TTM)

$248.24B

6.67

14.88

1.26

89.41%

13.85%

3.84%

4.24%

$74.37

201 days

Company Executives
Name Title
Casey Capparelli Executive Director of Investor Relations
Howard Y. Chang Senior Vice President of Global Research & Chief Scientific Officer
Matthew C. Busch Chief Accounting Officer & Vice President of Finance
Scott Skellenger Senior Vice President & Chief Information Officer
Nancy A. Grygiel Senior Vice President of Worldwide Compliance & Business Ethics and Chief Compliance Officer
Robert A. Bradway Chairman & CEO
Peter H. Griffith Executive Vice President & Chief Financial Officer
Jonathan Graham Executive Vice President, General Counsel & Secretary
James E. Bradner EVP of Research & Development, Artificial Intelligence and Data
David Reese Executive Vice President
Andrew H. Martin Senior VP & GM of U.S. Business Operations
Jasper van Grunsven Senior Vice President of Rare Disease, Global Commercial Capabilities & Innovation
Sean Bruich SVP & Chief Technology Officer
Som Chattopadhyay Senior Vice President of Global Business Solutions & National Executive
Murdo Gordon Executive Vice President of Global Markets and Policy
Sam Guhan Senior Vice President of Global Engineering
Esteban Santos Executive Vice President of Operations
Poll Results

No votes yet today — be the first to share your view!

About Amgen Inc. (NASDAQ:AMGN) Stock

Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteopo ... rosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.

Amgen submits new data to challenge FDA's proposal to withdraw Tavneos

2026-07-24 09:45:42

Amgen said on Friday it submitted new evidence to the FDA on July 23 as it seeks a ​hearing to challenge the proposed withdrawal of its ‌rare-disease drug Tavneos from the U.S. market.

Bank of Nova Scotia Has $110.56 Million Stock Position in Amgen Inc. $AMGN

2026-07-24 04:03:48

Bank of Nova Scotia reduced its holdings in Amgen Inc. (NASDAQ: AMGN) by 15.8% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 314,227 shares of the medical research company's stock after selling 58,745 shares during the period.

Amgen (AMGN) Rises As Market Takes a Dip: Key Facts

2026-07-23 18:51:14

Amgen (AMGN) concluded the recent trading session at $371.47, signifying a +1.48% move from its prior day's close.

Verizon Was Booted From the Dow – 5 Dividend Giants Got the Same Treatment and Eventually Soared

2026-07-23 08:13:31

Getting kicked off the Dow Jones Industrial Average sounds like a death sentence for a stock, but a handful of booted dividend giants went on to reward patient shareholders with stunning gains and steady income streams that index investors missed out on entirely.

Which iShares Healthcare ETF Is the Better Buy: Diversified IXJ or Biotech-Focused IBB?

2026-07-23 07:49:09

IBB delivered 44% returns in one year but swung 40% lower at its worst. IXJ grew steadily with half the volatility and a 1.5% dividend yield.

How retirees are earning $0.18 monthly per share without options risk

2026-07-22 09:06:30

DIVO quietly hands retirees a monthly check from a portfolio of blue-chip giants, but a 150% payout ratio and a debt-laden pharma holding raise fair questions about what is actually backing that income.

Amgen settles shareholder lawsuit claiming it hid $10.7 billion tax bill

2026-07-21 11:10:25

Amgen reached a $74 million settlement of a lawsuit accusing the biotechnology company of ​waiting too long to disclose that it might owe ‌the Internal Revenue Service $10.7 billion for underreporting six years of taxes.

Andra AP fonden Has $17.72 Million Stock Position in Amgen Inc. $AMGN

2026-07-21 03:58:00

Andra AP fonden cut its holdings in Amgen Inc. (NASDAQ: AMGN) by 18.9% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 50,366 shares of the medical research company's stock after selling 11,734 shares during the quarter. Andra AP fonden's holdings in

Frequently Asked Questions

What is the current Amgen Inc. (AMGN) stock price?

Amgen Inc.(NASDAQ:AMGN) stock price is $376.04 in the last trading session. During the trading session, AMGN stock reached the peak price of $391.29 while $269.77 was the lowest point it dropped to. The percentage change in AMGN stock occurred in the recent session was 1.22% while the dollar amount for the price change in AMGN stock was $4.54.

AMGN's industry and sector of operation?

The NASDAQ listed AMGN is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.

Who are the executives of AMGN?

Casey Capparelli | Executive Director of Investor Relations
Howard Y. Chang | Senior Vice President of Global Research & Chief Scientific Officer
Matthew C. Busch | Chief Accounting Officer & Vice President of Finance
Scott Skellenger | Senior Vice President & Chief Information Officer
Nancy A. Grygiel | Senior Vice President of Worldwide Compliance & Business Ethics and Chief Compliance Officer

How many employees does AMGN have?

Number of AMGN employees currently stands at 31500. AMGN operates from One Amgen Center Drive, Thousand Oaks, CA 91320-1799, US.

Link for AMGN official website?

Official Website of AMGN is: https://www.amgen.com

How do I contact AMGN?

AMGN could be contacted at phone #805 447 1000 and can also be accessed through its website. AMGN operates from One Amgen Center Drive, Thousand Oaks, CA 91320-1799, US.

How many shares of AMGN are traded daily?

The average number of AMGN shares traded daily for last 3 months was 2.72M.

What is the market cap of AMGN currently?

The market value of AMGN currently stands at $202.95B with its latest stock price at $376.04